Related Experiment Videos

Liposomes modulate human immunodeficiency virus infectivity

K Konopka1, B R Davis, C E Larsen

  • 1Cancer Research Institute, University of California, San Francisco 94143-0128.

Insights

Liposome fusion with human immunodeficiency virus type 1 (HIV-1) significantly alters viral infectivity. Certain liposomes enhance HIV-1 production and cell entry, while others inhibit it, impacting HIV-1

Area of Science:

  • Virology
  • Biotechnology
  • Cell Biology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) infects CD4+ cells.
  • Liposomes are lipid vesicles used in drug delivery and research.
  • Understanding HIV-1-liposome interactions is crucial for therapeutic strategies.

Purpose of the Study:

  • To investigate how liposome fusion affects HIV-1 infectivity.
  • To determine the impact of different liposome compositions on HIV-1 infection.
  • To explore liposome-mediated modulation of HIV-1 entry into target cells.

Main Methods:

  • Fusion assays using fluorescence dequenching to assess HIV-1 and liposome interaction.
  • Measuring HIV-1 production via p24 gag antigen quantification.
  • Infectivity assays using CD4+ (A3.01, H9) and CD4- (K562) cell lines.

Main Results:

  • HIV-1 fused with cardiolipin (CL) and N-[2,3-(dioleyloxy) propyl]-N,N,N-trimethyl ammonium chloride (DOTMA) liposomes, but not dioleoylphosphatidylcholine (DOPC) liposomes.
  • DOTMA liposomes enhanced HIV-1 production and infectivity in CD4+ cells by up to 90-fold.
  • CL liposomes inhibited HIV-1 infection in a concentration-dependent manner.
  • DOPC liposomes had no significant effect on HIV-1 infectivity.

Conclusions:

  • Liposome fusion with HIV-1 can significantly alter its infectivity.
  • Specific liposome compositions, like DOTMA, can enhance HIV-1 infection.
  • Other liposomes, like CL, can inhibit HIV-1 infection.
  • These findings highlight the potential for liposomes to modulate HIV-1-host cell interactions.

Related Concept Videos